Andrew Kenneth William Powell

Andrew Kenneth William Powell, listed as board member, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Aclaris Therapeutics, Inc., Lifecore Biomedical, Inc. \DE\ and Medivation, Inc. The record holds 18 filings, for trades running from 6 June 2016 to 1 June 2024.

In open-market terms, that means 3 purchases worth €23k on one side and 1 sale worth €137k on the other. Sales outweigh purchases by €114k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 4 share grants and 5 option exercises. In 2024 alone, the filings show 1 purchase and no sales.

A typical purchase (the median) is worth €8,090. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -21.1%. They describe history only and say nothing certain about the share price ahead.

On 4 June 2024 came the latest disclosure, an option exercise in Aclaris Therapeutics, Inc. The latest purchase dates back some time: it was published 963 days ago, on 5 March 2024. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.